Research on the predictive utility of urine tests in New York City and elsewhere suggests that urine screening and monitoring data do not improve the ability to classify high-risk offenders or reduce pretrial misconduct under supervised release programs. Universal prearraignment drug screening of arrestees to identify high-risk defendants is not likely to be cost-effective. Further, there is a need to be aware of the multidimensional nature of drug abuse and and to evaluate the efficacy of drug treatment as a condition of pretrial release. Coupled with technical and process concerns surrounding drug tests, evidence suggests caution in the adoption of pretrial drug testing programs. Policy and program issues associated with pretrial drug testing are explored that pertain to pretrial release and supervision, resources, drug testing technology, and constitutional and due process issues. 41 references, 6 notes, and 5 tables
Downloads
Similar Publications
- QCM-based screening of acrylate polymers for NPPA pre-concentration to enhance vapor detection of fentanyl
- Mental Health and Rape History in Relation to Non-Medical Use of Prescription Drugs in a National Sample of Women
- Race, Health, and Recidivism: Examining the Effects of Health Status and Healthcare Needs on Recidivism for Black and White Formerly Incarcerated People